Physician profile
Linzi Jiang
NPI 1225666241
$1,820.77
in general payments reported to CMS, 2019-2025
20 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.82 · 2021: $54.58 · 2023: $300 · 2024: $476 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.15 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $156.23 | 2025 | Inceptiv |
| Boston Scientific Corporation | $151.85 | 2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $143.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $141.49 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Abbvie INC. | $134.08 | 2023-2025 | |
| Saluda Medical Americas, INC. | $113.06 | 2023 | Evoke Scs |
| Exact Sciences Corporation | $89.01 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $81.68 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.72 | 2024-2025 | |
| Amgen INC. | $56.99 | 2024-2025 | Repatha, Otezla, Otezla |
| Emd Serono, INC. | $54.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.78 | 2024-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $29.67 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.33 | 2024 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $22.21 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $19.80 | 2024 | Quviviq |
| Dexcom, INC. | $19.41 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $14.82 | 2020 | |
| Esperion Therapeutics, INC. | $13.64 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linzi Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.